Gilgamesh Pharmaceuticals GTM brain

Gilgamesh discovers and develops investigational neuroscience medicines and partners with pharmaceutical companies to advance psychiatric programs.

category

Clinical-stage neuroscience therapeutics

market profile

  • text: Its pipeline targets depression, anxiety, substance use disorder and schizophrenia with distinct investigational mechanisms.
  • text: AbbVie acquired the original Gilgamesh entity in 2025; a new independent Gilgamesh Pharma retained employees and other programs, including the earlier collaboration.
  • text: Neuropsychiatric drug developers compete for licensing partners and clinical validation in a market with significant unmet need.

personas

  • title: Pharmaceutical neuroscience business development executive
    pains:
    • Needs differentiated assets and defensible intellectual property for a neuroscience pipeline
    • Must balance clinical uncertainty against deal economics and strategic fit
  • title: Psychiatry clinical development leader
    pains:
    • Must demonstrate efficacy and tolerability in rigorous trials
    • Existing treatments can leave patients with unmet needs or burdensome administration
  • title: Academic psychiatry trial investigator
    pains:
    • Needs protocols and suitable participants for investigational depression studies
    • Must communicate uncertainty and monitor safety as novel mechanisms are tested

icp

  • text: Large pharmaceutical companies with neuroscience licensing, clinical development and commercialization capacity, as illustrated by AbbVie.
  • text: Clinical research institutions with psychiatric trial capabilities are potential development collaborators; buyer size and geography are not specified.

message pillars

  • text: Aim for therapies that go beyond symptom management.
  • text: Combine chemistry with computational tools to develop new molecules.
  • text: Explore non-hallucinogenic neuroplasticity mechanisms.

objections

  • objection: Are the programs proven or available to prescribe?
    response: They are investigational; review program-specific trial results and regulatory status rather than assuming clinical benefit.
  • objection: Does the platform offer differentiated and licensable assets?
    response: Diligence individual chemistry, intellectual property, safety data and existing partner rights.

competitors

  • name: Vistagen Therapeutics
    why: Develops psychiatric candidates including an NMDA-related depression program.
  • name: Cybin
    why: Develops psychedelic-inspired therapies for overlapping psychiatric indications.
  • name: MindMed
    why: Develops clinical-stage treatments for psychiatric conditions and competes for partners and trial resources.

influencers

  • name: Jonathan Sporn
    url: https://www.gilgameshpharmaceutical.com/
    why: Founder and CEO articulating the company's therapeutic mission.

keywords

  • neuroplastogen drug development
  • rapid acting antidepressant trials
  • psychiatric drug licensing
  • non hallucinogenic neuroplasticity
  • NMDA antagonist depression
  • psychiatric biotech partnership

voice

  • Science-led
  • Ambitious
  • Mechanism-focused

signals

  • text: A pharmaceutical company announces a neuroscience licensing strategy or seeks external depression assets.
  • text: A trial site expands clinical research in depression or related neuropsychiatric disorders.

pricing

model: unknown

motion

sales_led

channels

  • Industry partnerships
  • Scientific and trade press

confidence

medium

Founders

  • name: JONATHAN SPORN
    title: Founder
    role: Founder
    bio: Duke University BS, MD from University of Miami, former Chief of Psychiatry in Boston Area. Academic work at Mass General Hospital and NIH (intramural), researcher at JNJ in psychiatry and neurology, and then at Pfizer Inc in NYC (Clinical Disease Area Expert in Neuroscience Area), Founder of start up, Perception Neuroscience (exited) and was CSO, and now Founder of Gilgamesh. Live in NYC and mountains of NC. Assistant Professor of Psychiatry and Exp Therapeutics at Columbia University
  • name: Andrew Kruegel
    title: Founder
    role: Founder
    bio: I am a medicinal chemist, pharmacologist, and entrepreneur with extensive experience in the design and preclinical development of psychoactive drugs for the future treatment of psychiatric illnesses. In the context of my entrepreneurial endeavors I have also built significant expertise in business, fundraising, operations, and intellectual property strategy.
  • name: Dalibor Sames
    title: Founder
    role: Founder
    bio: Professor of Chemistry at Columbia University with expertise in synthetic chemistry, medicinal chemistry, molecular design, synaptic imaging, neuropharmacology, and experimental therapeutics. Led new conceptual advances in chemical synthesis (C-H bond functionalization), developed fluorescent false neurotransmitters (FFNs), elucidated the mechanism of action of antidepressant tianeptine, expertise in iboga alkaloid and mitragynines chemistry and pharmacology.

Back to YC companies